Omnihealth Practice

CARDIOLOGY

PFA may offer a time-efficient and safer alternative for drug-refractory AF patients

28 Apr 2023

Safety of rosuvastatin mirrors common cholesterol supplements with enhanced lipid modulation

09 May 2024

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

P2Y12i monotherapy as a new and better alternative for long-term secondary prevention of CAD: The PANTHER study and case sharing

08 May 2023

A local case sharing: earlier evolocumab for better long-term outcomes in patients with established ASCVD

09 Feb 2023

From conventional to leadless pacemaker: Real-world experience, challenges and future prospects

21 Nov 2022

Insightful experience: SGLT2i to treat heart failure with reduced ejection fraction

31 Mar 2022

Evolocumab as added value for plaque stabilization and regression in statin-treated CAD patients

02 Dec 2021

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

21 Sep 2021

Breaking the vicious cycle of cardiac, renal and metabolic risks in patients at risk of chronic kidney disease

13 Jul 2021

Early screening for familial hypercholesterolemia helps optimize the additional LDL-lowering benefit of add-on PCSK9 inhibitor

17 Jun 2021

Dapagliflozin as the first step to heart failure quadruple therapy: Sharing of local cases

25 May 2021

Dapagliflozin as a treatment reduces worsening heart failure and cardiovascular death among heart failure patients

28 Feb 2021

Evolocumab greatly reduces low-density lipoprotein cholesterol levels in familial hypercholesterolemia: A local case review

30 Oct 2020

Prolonged use of DAPT with ticagrelor in a high-risk post-myocardial infarction patient: A local case report

01 Sep 2020

A case of patient with recurrent cardiovascular events stabilized by evolocumab in Hong Kong

29 Jun 2020

Evolocumab lowers lipoprotein(a) levels in triple-vessel coronary artery disease: A local case report

29 Apr 2020

A case review on cardiac risk stratification in the secondary prevention of cardiovascular diseases

28 Feb 2020

Overcoming the challenging journey: Secondary prevention of CV events with PCSK9i

30 Oct 2019

Self-care is the key in the management of chronic heart failure

31 Oct 2019

A local case sharing: Key strategies to identify statin intolerance followed by aggressive lipid-lowering treatment

06 Jul 2021

Where clopidogrel fails: The struggle with CYP2C19 polymorphisms in the treatment of neurovascular diseases

03 Jan 2024

From conventional to leadless pacemaker: Real-world experience, challenges and future prospects

In recent years, leadless pacemaker has been introduced into clinical practice to overcome the lead- and pocket-related complications associated with conventional pacemakers, including infections and lead failure.^1-4 In the absence of subcutaneous pocket and leads, leadless pacemaker is a promising technology that could potentially change the approach of arrhythmia management, particularly for patients with increased risks of infections.^5,6 In an interview with Omnihealth Practice, Dr. Lee, Lai-Fun Kathy discussed the emerging role of leadless pacemakers in local practice and the ongoing challenges with the leadless pacing. She also shared a local clinical case to demonstrate the benefits of leadless pacemakers in a 95-year-old arrhythmia patient.

21 Nov 2022

Dr. Lee, Lai-Fun Kathy

Specialist in Cardiology

Insightful experience: SGLT2i to treat heart failure with reduced ejection fraction

Heart failure (HF) is global pandemic affecting at least 26 million people worldwide in 2017 and has been increasing in prevalence.¹ In 2020, HF plus other heart diseases caused an age-standardized death rate of 34.0 per 100,000 standard population in Hong Kong.²Previously, patients with HF with reduced ejection fraction (HFrEF) were treated with a foundational triple therapy including β-blockers, renin-angiotensin system inhibitors [including angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs)] or angiotensin receptor-neprilysin inhibitors (ARNIs), as well as mineralocorticoid receptor antagonists (MRAs).³ With reference to the recent data supporting the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with chronic HFrEF regardless of the diabetes status, it is noted that comprehensive diseasemodifying quadruple therapy has now become the new standard of care for HFrEF patients.^4,5 In a recent interview with Omnihealth Practice, Professor Siu, Chung-Wah David shared his insights on the application of SGLT2i in HFrEF treatment.

31 Mar 2022

Professor Siu, Chung-Wah, David

Clinical Professor,
Department of Medicine,
The University of Hong Kong

ACC 2024

April 6-8, 2024 | Atlanta, United States

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

CARDIOLOGY DIABETES & ENDOCRINOLOGY

21 Sep 2021

Professor Jonathan Shaw

Deputy Director,
Clinical and Population Health,
Baker Heart and Diabetes Institute,
Melbourne, Australia

Safety of rosuvastatin mirrors common cholesterol supplements with enhanced lipid modulation

In brief Dietary supplements are commonly used by individuals with indications for lipid-lowering therapy.1 However, their effectiveness in reducing low-density lipoprotein cholesterol (LDL-C) has not been sufficiently studied, especially when compared with statins.1 A single-center, prospective, r

09 May 2024

J Am Coll Cardiol. 2023

Laffin LJ, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.

A local case sharing: earlier evolocumab for better long-term outcomes in patients with established ASCVD

Atherosclerotic cardiovascular disease (ASCVD) continuesto be a leading cause of morbidity and mortality worldwide,with over 17.9 million people dying from cardiovascular (CV)diseases annually.1,2 Given the fact that the recurrent riskis high among patients with established ASCVD, secondarypreventio

09 Feb 2023

Dr. Kwok, On-Hing Vincent

Director, Cardiology Centre
Hong Kong Sanatorium & Hospital
Honorary Clinical Associate Professor,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

Computational pressure-flow dynamics-derived FFR offers clinically meaningful and durable prognostic responses among patients with stable CAD

In the treatment of coronary artery disease (CAD), fractional flow reserve (FFR) can be performed during coronary angiography to evaluate the need for percutaneous coronary intervention (PCI).1 Nevertheless, the efficacy of wire-based FFR is constrained by its practical limitations.1,2 Computational

03 Jan 2024

Bempedoic acid receives FDA approvaal for expanded indication in CVD Prevention

Bempedoic acid inhibits ATP citrate lyase, an enzyme upstream of 3-hydroxy-3-methalglutaryl-coenzyme (HMG-CoA) reductase which is the rate-limiting step of cholesterol biosynthesis.1,2 This reduces hepatic cholesterol synthesis and raises LDL receptor expression, increasing the clearance of LDL-C fr

23 Apr 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024